SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mancilla Edna E)
 

Sökning: WFRF:(Mancilla Edna E) > Reduction of new he...

  • Pignolo, Robert J.Department of Medicine, Mayo Clinic, MN, Rochester, United States (författare)

Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP)

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2023-01-25
  • John Wiley & Sons,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-204678
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-204678URI
  • https://doi.org/10.1002/jbmr.4762DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, severely disabling genetic disorder of progressive heterotopic ossification (HO). The single-arm, open-label, phase 3 MOVE trial (NCT03312634) assessed efficacy and safety of palovarotene, a selective retinoic acid receptor gamma agonist, in patients with FOP. Findings were compared with FOP natural history study (NHS; NCT02322255) participants untreated beyond standard of care. Patients aged ≥4 years received palovarotene once daily (chronic: 5 mg; flare-up: 20 mg for 4 weeks, then 10 mg for ≥8 weeks; weight-adjusted if skeletally immature). The primary endpoint was annualized change in new HO volume versus NHS participants (by low-dose whole-body computed tomography [WBCT]), analyzed using a Bayesian compound Poisson model (BcPM) with square-root transformation. Twelve-month interim analyses met futility criteria; dosing was paused. An independent Data Monitoring Committee recommended trial continuation. Post hoc 18-month interim analyses utilized BcPM with square-root transformation and HO data collapsed to equalize MOVE and NHS visit schedules, BcPM without transformation, and weighted linear mixed-effects (wLME) models, alongside prespecified analysis. Safety was assessed throughout. Eighteen-month interim analyses included 97 MOVE and 101 NHS individuals with post-baseline WBCT. BcPM analyses without transformation showed 99.4% probability of any reduction in new HO with palovarotene versus NHS participants (with transformation: 65.4%). Mean annualized new HO volume was 60% lower in MOVE versus the NHS. wLME results were similar (54% reduction fitted; nominal p = 0.039). All palovarotene-treated patients reported ≥1 adverse event (AE); 97.0% reported ≥1 retinoid-associated AE; 29.3% reported ≥1 serious AE, including premature physeal closure (PPC)/epiphyseal disorder in 21/57 (36.8%) patients aged <14 years. Post hoc computational analyses using WBCT showed decreased vertebral bone mineral density, content, and strength, and increased vertebral fracture risk in palovarotene-treated patients. Thus, post hoc analyses showed evidence for efficacy of palovarotene in reducing new HO in FOP, but high risk of PPC in skeletally immature patients.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hsiao, Edward C.Division of Endocrinology and Metabolism, the UCSF Metabolic Bone Clinic, the Eli and Edythe Broad Institute for Regeneration Medicine, and the Institute of Human Genetics, Department of Medicine, and the UCSF Program in Craniofacial Biology, University of California-San Francisco, CA, San Francisco, United States (författare)
  • Al Mukaddam, MonaDepartments of Orthopaedic Surgery & Medicine, The Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, PA, Philadelphia, United States (författare)
  • Baujat, GenevièveDépartement de Génétique, Institut IMAGINE and Hôpital Universitaire Necker-Enfants Malades, Paris, France (författare)
  • Berglund, Staffan K.Umeå universitet,Pediatrik(Swepub:umu)stnbed99 (författare)
  • Brown, Matthew A.Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Genomics England Ltd, London, United Kingdom (författare)
  • Cheung, Angela M.Department of Medicine and Joint Department of Medical Imaging, University Health Network, University of Toronto, ON, Toronto, Canada (författare)
  • De Cunto, CarmenPediatric Rheumatology Section, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina (författare)
  • Delai, PatriciaCentro de Pesquisa Clinica, Hospital Israelita Albert Einstein, São Paulo, Brazil (författare)
  • Haga, NobuhikoDepartment of Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan (författare)
  • Kannu, PeterHospital for Sick Children, ON, Toronto, Canada (författare)
  • Keen, RichardCentre for Metabolic Bone Disease, Royal National Orthopaedic Hospital, Stanmore, United Kingdom (författare)
  • Le Quan Sang, Kim-HanhDépartement de Génétique, Institut IMAGINE and Hôpital Universitaire Necker-Enfants Malades, Paris, France (författare)
  • Mancilla, Edna E.Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, PA, Philadelphia, United States (författare)
  • Marino, RoseIpsen, MA, Cambridge, United States (författare)
  • Strahs, AndrewIpsen, MA, Cambridge, United States (författare)
  • Kaplan, Frederick S.Departments of Orthopaedic Surgery & Medicine, The Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, PA, Philadelphia, United States (författare)
  • Department of Medicine, Mayo Clinic, MN, Rochester, United StatesDivision of Endocrinology and Metabolism, the UCSF Metabolic Bone Clinic, the Eli and Edythe Broad Institute for Regeneration Medicine, and the Institute of Human Genetics, Department of Medicine, and the UCSF Program in Craniofacial Biology, University of California-San Francisco, CA, San Francisco, United States (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Bone and Mineral Research: John Wiley & Sons38:3, s. 381-3940884-04311523-4681

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy